Perrigo stock
PRGONYSEPerrigo Company plc, HealthcareISIN IE00BGH1M568
48Score 48 out of 100, Weak
Price and trend
89 / 100
Price history
+16% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 32% above it.
Since September 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 53).
The price is 2.4% below its 52-week high. Largest decline in 20 years: 95% (April 2015 to March 2026).
Chart figures for advanced users
- SMA 50$15.09
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$12.50
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)53
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$9.25
- The lowest closing price of the last twelve months.
- Resistance$16.95
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Perrigo Company plc belongs to the Drug Manufacturers (Specialty & Generic) industry (Ireland) and, with a market value of $2.3B, is number 50 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.25B (down 2.8% year on year) and a loss of $1.43B.
- MEQIRI Score 48 out of 100 (Weak): rank 407 of 714 in Healthcare, median 53.
Show more
- Our model puts fair value at $16.64, with the price 1% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- High dividend yieldDividend yield 7.01%, Drug Manufacturers (Specialty & Generic) median 1.74%.
- Reliable dividendNo dividend cut for 23 years.
Weaknesses
- Loss-makingLoss of $1.77B over the last 12 months.Fundamentals 41
- High debtDebt 1.35 times equity (latest quarter), Drug Manufacturers (Specialty & Generic) median 0.49.Stability 44
- Volatile share priceVolatility 50% a year over the last 12 months.Stability 44
Its standout strengths are technical analysis and momentum, while growth and profitability hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
- high price swings
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $11.89 and expensive above $27.74 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 12.2%. At 13.2% the fair value would be $14.95, at 11.2% it would be $18.79.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 26 Sep 2026, revenue fell 4.5% on the twelve months before. Revenue has grown solidly since 2005, at about 6% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 35%, operating 8%, net −34%. Last 12 months: net −43%.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 4 Nov 2026EPS reported $0.60 (expected $0.51)above expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 3.6% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $2.29+3.9%
- Revenue
- $3.99B−1.6%
- Earnings per share
- $2.31−3.6%
- Revenue
- $3.9B−4.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +16.3%2026 outlook for net sales, margin and EPS reaffirmed and deliberately not raised because the quarter benefited from one-time items.
“As indicated previously, planned under-absorption stemming from lower prior year sales volumes is expected to result in an unfavorable all-in earnings per share impact of approximately $0.60 in 2026.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 5 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
- Parker Geoffrey M.Purchase
12 Nov 2025, Board
- Shares
- 7,500
- Price
- $14.18
- Value
- $106,350
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Perrigo
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 48
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- Bausch Health CompaniesBHC $3.13B61
- Regencell Bioscience HoldingsRGC $2.68B31
- HUTCHMED (China)HCM $2.63B45
- AlmirallALM.MC $2.61B45
- Trulieve CannabisTRLV $2.17B48
- Dermapharm HoldingDMP.DE $2.13B68
- FagronFAGR.BR $1.99B70
- Eton PharmaceuticalsETON $1.97B69
ETFs that hold Perrigo
Held by 6 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.12% | 0.30% | €2.28B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.02% | 0.35% | €8.19B |
Show 3 more
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2020)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.